Placebo-adjusted mean weight loss of 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks with no evidence of weight loss plateau in ...

Structure Therapeutics' Phase 2 data for Aleniglipron show 16% weight loss at 44 weeks with strong tolerability and no safety signals. Read more on GPCR stock.

Rapid technological advancements and the huge sums of money flowing into the data center are posing both risks and rewards ...

SpaceX’s potential $1.75T IPO could reshape markets. Learn how investors can gain exposure through XOVR ETF and why structure ...

A 30,000-square-foot warehouse in East Bakersfield caught fire Saturday around 2 p.m., marking the third time in less than ...

Chinese AI startup StepFun plans to drop its offshore structure as it prepares for an IPO. This signals a strategic shift aligned with regulatory and market dyn ...

Nutshell reports that transitioning from spreadsheets to CRM can be challenging due to data quality issues, longer timelines, ...

Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason ...

We used Tonic Fabricate to generate a fully synthetic email corpus, then RL fine-tuned an open-source model against it. The ...

Crypto whales are positioning aggressively ahead of the March CPI print releasing today. Here is what on-chain data reveals.